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Abstract The myeloproliferative neoplasms (MPN) and
myelodysplastic syndromes (MDS) occasionally demonstrate
overlapping morphological features including hypercellular-
ity, mild/nonspecific dysplastic changes and variable bone
marrow fibrosis. Thus, when the associated bone marrow
fibrosis results in a suboptimal specimen for morphological
evaluation, the descriptive diagnosis “fibrotic marrow with
features indeterminate for MDS versus MPN” is often ap-
plied. The JAK2
V617F mutation was recently shown to be
frequently identified in MPN, but it is rarely present in other
myeloid disorders. However, the diagnostic utility of
JAK2
V617F screening in hypercellular bone marrow speci-
mens with fibrosis has not been previously investigated.
Using a real-time polymerase chain reaction melting-curve
assay capable of detecting JAK2
V617F in archived fixed
materials, we retrospectively studied JAK2
V617F in 45 cases
with fibrotic hypercellular bone marrow at initial presenta-
tion, including 19 cases initially described as “with features
indeterminate for MDS versus MPN”. These 19 cases were
reclassified into more specific categories of MDS (n=14) or
MPN (n=5) based on the availability of subsequent clinical
data and/or bone marrow examinations. The JAK2
V617F
allele was identified in 17 out of 18 BCR/ABL gene-
negative MPN cases with marrow fibrosis, whereas only
wild-type alleles were identified in the remaining non-MPN
cases. Importantly, JAK2
V617F alleles were seen in all five
cases of “with features indeterminate for MDS versus MPN”
at initial presentation that were later determined to be MPN,
but they were absent in the 14 cases later determined to be
MDS. Our results suggest that JAK2
V617F allele evaluation
can be a useful ancillary test for discriminating MDS from
MPN in specimens with bone marrow fibrosis.
Keywords Myeloproliferativeneoplasm.
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Introduction
The myeloproliferative neoplasms (MPN, also known as
chronic myeloproliferative disorders or MPD) and myelo-
dysplastic syndromes (MDS) are usually distinguished by
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e-mail: jeffchang@tmhs.orgtheir clinical presentation, laboratory parameters, and mor-
phological appearance. However, they occasionally demon-
strate overlapping features including the coexisting presence
of mild hypercellularity, mild/nonspecific dysplasia, and
variable bone marrow fibrosis [1, 2]. Cases with fibrosis
may be problematic due to the difficulties associated with
obtaining an adequate aspirate smear specimen for optimal
microscopic examination, particularly when complete clin-
ical information and/or a peripheral blood smear is not
available. In these cases, descriptive diagnoses, such as
“with features indeterminate for MDS versus MPN”, are
usually given, and follow-up biopsies may be necessary for
rendering specific diagnoses. New molecular markers that
better discriminate these morphologically similar but biolog-
ically distinct entities could significantly improve clinical
management and facilitate research studies by providing
accurate diagnoses at the time of initial presentation [1–3].
A specific mutation in the Janus kinase 2 gene
(JAK2
V617F) was recently shown to be frequently and pref-
erentially identified in the bone marrow and peripheral blood
cells of MPN patients [1, 2, 4–20]. The JAK2
V617F allele has
been detected in the vast majority of polycythemia vera (PV)
cases, in the majority of essential thrombocytosis (ET) and
primary myelofibrosis (PMF) cases, and in many acute leu-
kemias representing transformation from preexisting MPN.
However, JAK2
V617F is rarely identified in healthy controls
or patients with other myeloid disorders. Thus, JAK2
V617F
has general diagnostic value for MPN, but it cannot be used
to differentiate between PV, ET, or PMF [1, 2, 4–19].
The diagnostic utility of JAK2
V617F mutation screening
in hypercellular bone marrow specimens with fibrosis has
not been previously investigated. We retrospectively evalu-
ated the JAK2 genotype of 45 fibrotic bone marrow
specimens, including 19 cases that were originally diagnosed
as “with features indeterminate for MDS versus MPN” using
our assay that reliably detects JAK2
V617F in archived and
paraffin-embedded materials [20, 21]. Our results demon-
strated that the presence or absence of JAK2
V617F may have
diagnostic implications for these cases.
Materials and methods
Patient samples
Archival pathology and hematology records at our respec-
tive institutions were retrospectively reviewed to identify
patients with a mildly to markedly fibrotic bone marrow
biopsy at initial marrow evaluation. Using reticulin and
collagen stains, fibrosis was graded on a scale of 0 to 3 as
previously described [22]. For PMF cases, grade 1 was
considered the early/prefibrotic stage (also termed cellular
phase) and grades 2–3 was considered the fibrotic stage
[22, 23]. The cohort was limited to nonchronic myelogenous
leukemia (BCR/ABL fusion gene negative) patients with
adequate history and follow-up for clinicopathologic corre-
lation. Forty-five specimens were identified as follows: 19
cases initially assigned to “with features indeterminate for
MDS versus MPN” because of fibrosis-associated inade-
q u a t ea s p i r a t ea n d / o rl a c ko fc o m p l e t ec l i n i c a li n f o r m a t i o n ,
11 cases with a confirmed MPN (two PMF prefibrotic stage,
four PMF fibrotic stage, three PV at spent phase, two ET,
and four PMF), two cases with acute myelogenous leukemia
(AML) transformed from a preexisting PMF, two cases with
chronic myelomonocytic leukemia, and 11 cases with other
neoplastic myeloid disorders (Table 1). None of these cases
were tested for JAK2 mutation at the time of initial
evaluation. This study was approved by the Institutional
Review Board of all participating institutions, and samples
were obtained in accordance with institutional policies.
DNA extraction and real-time PCR melting curve analysis
for JAK2 genotype
For each case, DNA was extracted from stained or un-
stained peripheral blood smears, stained or unstained bone
marrow aspirate smears, or formalin-fixed paraffin-embedded
bone marrow clot sections using the DNeasy Tissue Kit
(Qiagen, Valencia, CA, USA) as previously described [20,
21]. There was a relatively even distribution of each speci-
men type within each disease category (Table 1). Real-time
polymerase chain reaction (PCR) melting curve analysis for
the JAK2 wild-type and V617F mutant allele was performed
on a LightCycler platform (Roche Applied Diagnostics,
Indianapolis, IN, USA) using primers and probes as
previously described [20, 21]. Briefly, PCR primers were
designed to flank codon 617 of the JAK2 gene, including
forward primer JAKLCFP 5′-AAg CAg CAA gTATgATgA
gCA A-3′ and reverse primer JAKLCRP 5′-AgC TgT gAT
CCT gAA ACT gAA-3′. FRET probes were designed with
the 5′ probe overlapping the mutated codon and the 3′ probe
annealing immediately downstream, including LCRD 5′-
640-CAg ACA CAT ACT CCA TAA TTT-3′ and LCFN 5′-
gTA gTT TTA CTT ACT CTC gTC TC-FITC-3′. Real-time
PCR was performed on each specimen using 5.0 μLo f
purified DNA extract in a total reaction volume of 20 μL
that included 4 μL of FastStart DNA MasterPLUS SYBR
Green I 5× reaction master mix (Roche Applied Science),
2.0 μL JAK2LCFP (final concentration 0.5 μM), 2.0 μL
JAK2LCRP (final concentration 0.5 μM), 1.0 μLL C F N
(final concentration 0.5 μM), 1.0 μL LCRD (final concen-
tration 0.5 μM), and 5.0 μL nuclease-free water. The PCR
cycle parameters were one initial denaturing step of 95°C for
10 min and 55 cycles consisting of 95°C for 10 s, 60°C for
60 s, and 75°C for 10 s. The DNA melting curve analysis
was performed by denaturing at 95°C for 10 s, annealing at
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V617F genotyping in fibrotic bone marrow specimens
Case
no.
Specimen type
used for molecular
testing
Initial diagnosis assigned based on first
diagnostic evaluation
Final diagnosis
following subsequent
clinical–morphological
evaluations
Fibrosis
(grades 0–3)
JAK2
genotype
1 Aspirate “Features indeterminate for MDS versus MPN” Prefibrotic CIMF 1 Mutant
2 Clot section “Features indeterminate for MDS versus MPN” Prefibrotic CIMF 1 Mutant
3 Peripheral blood “Features indeterminate for MDS versus MPN” Prefibrotic CIMF 1 Mutant
4 Clot section “Features indeterminate for MDS versus MPN” CIMF, fibrotic stage 3 Mutant
5 Aspirate “Features indeterminate for MDS versus MPN” CIMF, fibrotic stage 3 Mutant
6 Aspirate “Features indeterminate for MDS versus MPN” MDS-F 2 Wild type
7 Peripheral blood “Features indeterminate for MDS versus MPN” MDS-F 3 Wild type
8 Aspirate “Features indeterminate for MDS versus MPN” MDS-F 3 Wild type
9 Aspirate “Features indeterminate for MDS versus MPN” MDS-F 2 Wild type
10 Aspirate “Features indeterminate for MDS versus MPN” MDS-F 2 Wild type
11 Aspirate “Features indeterminate for MDS versus MPN” MDS-F 3 Wild type
12 Aspirate “Features indeterminate for MDS versus MPN” MDS-F 3 Wild type
13 Peripheral blood “Features indeterminate for MDS versus MPN” MDS-F 3 Wild type
14 Peripheral blood “Features indeterminate for MDS versus MPN” MDS-F 1 Wild type
15 Peripheral blood “Features indeterminate for MDS versus MPN” MDS-F 2 Wild type
16 Peripheral blood “Features indeterminate for MDS versus MPN” MDS-F 2 Wild type
17 Peripheral blood “Features indeterminate for MDS versus MPN” MDS-F 2 Wild type
18 Clot section “Features indeterminate for MDS versus MPN” MDS-F 2 Wild type
19 Clot section “Features indeterminate for MDS versus MPN” MDS-F 2 Wild type
20 Aspirate Prefibrotic CIMF prefibrotic CIMF 1 Mutant
21 Clot section Prefibrotic CIMF prefibrotic CIMF 1 Mutant
22 Clot section CIMF, fibrotic stage CIMF, fibrotic stage 3 Mutant
23 Clot section CIMF, fibrotic stage CIMF, fibrotic stage 3 Mutant
24 Clot section CIMF, fibrotic stage CIMF, fibrotic stage 3 Mutant
25 Peripheral blood CIMF, fibrotic stage CIMF, fibrotic stage 3 Mutant
26 Aspirate AML transformed from CIMF AML transformed from CIMF 3 Mutant
27 Aspirate AML transformed from CIMF AML transformed from CIMF 2 Mutant
28 Aspirate ET with mild fibrosis ET with mild fibrosis 1 Mutant
29 Aspirate ET with mild fibrosis ET with mild fibrosis 1 Wild type
30 Aspirate PV, PPMM PV/PPMM 3 Mutant
31 Peripheral blood PV, PPMM PV/PPMM 3 Mutant
32 Peripheral blood PV, PPMM PV/PPMM 3 Mutant
33 Aspirate ALL with marked fibrosis ALL with marked fibrosis 3 Wild type
34 Aspirate ALL with marked fibrosis ALL with marked fibrosis 3 Wild type
35 Aspirate ALL with marked fibrosis ALL with marked fibrosis 3 Wild type
36 Aspirate AML with mild fibrosis AML with mild fibrosis 1 Wild type
37 Aspirate AML with moderate fibrosis AML with moderate fibrosis 2 Wild type
38 Aspirate AML with moderate fibrosis AML with moderate fibrosis 2 Wild type
39 Aspirate AML with moderate fibrosis AML with moderate fibrosis 2 Wild type
40 Aspirate CLL with mild fibrosis CLL with mild fibrosis 1 Wild type
41 Aspirate CMML with t(5;12), eosinophilia & fibrosis CMML with t(5;12), eosinophilia
& fibrosis
2 Wild type
42 Peripheral blood CMML with moderate fibrosis CMML with secondary fibrosis 2 Wild type
43 Aspirate LGL leukemia with moderate fibrosis LGL leukemia with secondary fibrosis 2 Wild type
44 Aspirate Mastocytosis with fibrosis Mastocytosis with fibrosis 3 Wild type
45 Aspirate TCC with secondary fibrosis TCC with secondary fibrosis 3 Wild type
Cases 1–19 were originally descriptively diagnosed as “with features indeterminate for MDS versus MPN” due to insufficient clinicopathological
evidence for a specific diagnosis, but each was later reclassified, independent of JAK2 allele status, as either CIMF or MDS with myelofibrosis
(MDS-F) based on the evaluation of subsequent bone marrow specimens and correlation with clinical disease progression. JAK2 genotype is
reported as wild-type or mutant, and fibrosis is graded on a scale of 0–3.
MDS Myelodysplastic syndromes, MPN myeloproliferative neoplasms, CIMF chronic idiopathic myelofibrosis, AML acute myeloid leukemia, ET
essential thrombocythemia, PV polycythemia vera, PPMM post-polycythemic myeloid metaplasia, ALL acute lymphoblastic leukemia, CLL
chronic lymphocytic leukemia, CMML chronic myelomonocytic leukemia, LGL large granular lymphocyte, TCC transitional cell carcinoma
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70 C. Melting curves were visually analyzed, and the melting
temperature (Tm) of each sample was electronically recorded.
Homozygous mutant (JAK2
V617F/JAK2
V617F) human erythro-
leukemia (HEL) and homozygous wild-type (JAK2/JAK2)
multiple myeloma (RPMI8226) cell lines were used as
positive and negative controls, respectively (Fig. 1).
Results
Medical records and bone marrow specimens obtained at
subsequent evaluations were reviewed for all the patients to
render final diagnoses using World Health Organization
criteria to the fullest extent possible [1, 23–25]. Of note, the
19 cases initially designated as “with features indeterminate
for MDS versus MPN” were ultimately reclassified as
either PMF (n=5) or MDS with myelofibrosis (MDS-F, n=
14; Table 1) based on repeat/follow-up biopsies and/or
clinical progression. None of these cases fulfilled the
criteria for the diagnosis of MDS/MPN according to
WHO classification. The blast count in the cases finally
diagnosed as MDS-F could not be accurately evaluated due
to inadequate marrow smear, and thus, a definite subtype of
MDS could not be assigned accurately. However, the CD34
stain showed an increase of blasts in the majority of these
cases, suggesting they were high-grade MDS (refractory
anemia with excess of blasts). All diagnoses were assigned
without the prior knowledge of JAK2 mutation testing
results.
The JAK2 gene was successfully amplified by our real-
time PCR melting curve assay in all 45 cases (examples
shown in Fig. 1). The mutant allele was detected in 17 out
of 18 (94%) patients with a MPN (according to the final
diagnosis in Table 1), including five out of five cases of
prefibrotic PMF, six out of six cases of PMF in the fibrotic
stage, two out of two cases of AML transformed from
preexisting PMF, one out of two cases of ET with fibrosis,
and three out of three cases of PV with fibrosis (also termed
post-polycythemic myeloid metaplasia, PPMM; Table 1).
Only the wild-type allele was detected in 27 out of 27
(100%) patients with other neoplastic myeloid disorders
associated with fibrosis, including 14 out of 14 cases of
MDS-F, three out of three cases of ALL with marked fibrosis,
four out of four cases of AML with mild to moderate fibrosis,
two out of two cases of CMML with moderate fibrosis, one
out of one case of CLL with mild fibrosis, one out of one case
of large granular lymphocytic leukemia with moderate
fibrosis, one out of one case of mastocytosis with marked
fibrosis, and one out of one case of metastatic transitional cell
carcinoma with marked fibrosis (Table 1).
Of note, 19 cases (Table 1, cases 1–19) were originally
descriptively diagnosed as “with features indeterminate for
MDS versus MPN” due to insufficient clinicopathological
evidence for definitive categorization. Figure 2 illustrates
the significant overlapping features of MDS and MPN in
Fig. 1 Representative JAK2 real-time PCR melting curves. Melting
curves are drawn with −dF/dT on the y-axis and melting temperature
(TM,°C) on the x-axis. The homozygous wild-type (JAK2/JAK2)
multiple myeloma control cell line (RPMI 8226) is shown in red with
the melting curve peak at approximately 56°C (TM=56°C), and the
homozygous mutant (JAK2
V617F/JAK2
V617F) human erythroleukemia
control cell line (HEL) is shown in blue with the melting curve peak at
approximately 47°C (TM=47°C). A representative case of MDS-F
(JAK2 wild type) is shown in yellow with a single TM equivalent to
the wild-type JAK2 allele. A representative case of prefibrotic PMF
(heterozygous JAK2/JAK2
V617F) is shown in green with two TM; one
peak corresponds to the JAK2 wild-type allele and the other
corresponds to the JAK2
V617F mutant allele
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A to C) was later determined to be prefibrotic PMF, and the
other was reclassified as MDS-F with additional data
obtained from follow-up biopsies and/or clinical findings.
Importantly, JAK2
V617F mutant alleles were detected in all
cases reclassified as PMF (Table 1, cases 1–5), whereas
only JAK2 wild-type alleles were detected in all cases
reclassified as MDS-F (Table 1, cases 6–19).
Discussion
Our results suggest that JAK2
V617F mutation screening is an
important ancillary test for distinguishing between MDS
and other BCR-ABL negative MPN with marrow fibrosis.
Distinction between MPN and MDS is important for the
appropriate clinical management of hematology patients.
However, some cases may occasionally demonstrate over-
lapping morphological, laboratory, and clinical features that
result in considerable diagnostic difficulty, particularly
when the marrow aspirate is not optimal for morphologic
evaluation due to the associated marrow fibrosis and when
clinical data is limited or peripheral blood smears are
unavailable for review. Our results demonstrated that
JAK2
V617F was detected in nearly all cases of BCR-ABL
negative MPN with fibrosis (Table 1). Only one case of
JAK2
V617F-negative ET was identified. This particular
patient may carry one of the other more rare JAK2 or
MPL mutations not detected by our real-time PCR assay
[26, 27]. In comparison, only wild-type alleles were
detected in each case diagnosed as a non-MPN myeloid
disorder with marrow fibrosis (Table 1). Other reports have
Fig. 2 Microscopic evaluation
of fibrotic bone marrow speci-
mens. Representative micro-
graphs of two cases with fibrotic
marrow and “features indeter-
minate for MDS versus MPN”
at the time of initial clinical
presentation, that were later
reclassified as PMF (a–c) and
MDS-F (d–f). Low power
(a and d, respectively), high
power (b and e, respectively),
and reticulin stains (c and f,
respectively) are shown. Both
cases demonstrate overlapping
morphological features includ-
ing hypercellularity, mild dys-
plasia and fibrosis, making a
definitive diagnosis difficult.
b demonstrates the increased
bizarre megakaryocytes often
observed in PMF, and e demon-
strates the mononucleated meg-
akaryocytes often seen in MDS.
However, the morphologic
evaluation alone as shown at
initial presentation is not suffi-
cient to render a specific diag-
nosis without follow-up biopsies
and additional clinical findings
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V617F in
MDS/MPN cases, including chronic myelomonocytic leu-
kemia and atypical chronic myelogenous leukemia [28–30].
However, compared to MPN, a lower frequency of JAK2
mutations was identified. Taken together, analysis of the
JAK2 mutation, in difficult-to-classify cases, will help to
clarify the borderline between MDS (lacking JAK2 muta-
tion) on one hand, and atypical MPN and MDS/MPN on
the other hand. It would have been interesting to also
include cases of autoimmune-associated marrow fibrosis,
another setting that may mimic MPN or MDS associated
with marrow fibrosis. However, no cases were found in our
patient databases. Additionally, in our series, we found that
acute leukemia arising in PMF retain the JAK2
V617F-
positive genotype, whereas no JAK2 mutations were found
in de novo AML with fibrosis. Since AML transformed
from a preexisting MPN has a poorer overall prognosis,
JAK2 genotyping may also have value in stratifying risk
groups or predicting therapeutic responses in acute myeloid
leukemia patients [31, 32].
Our observations suggest that JAK2
V617F testing is
particularly helpful for cases with marrow fibrosis that are
difficult to classify into MDS or MPN at the initial
presentation [26]. Among the 19 specimens initially
described as “with features indeterminate for MDS versus
MPN”, JAK2
V617F mutant alleles were detected in each case
that was ultimately reclassified as PMF (Table 1, cases 1–5),
whereas only wild-type alleles were detected in the cases
eventually reclassified as MDS-F (Table 1, cases 6–19).
Although each patient was reclassified based on the
evaluation of subsequent morphological and clinical infor-
mation, JAK2
V617F genotyping could have substantially
aided diagnosis at the time of initial presentation since the
retrospective JAK2
V617F studies were concordant with the
final disease phenotype. The JAK genotyping results,
together with other clinical–morphological data and follow-
up information, will be important for rendering a definitive
diagnosis as early as possible during the disease course. This
will emerge as an increasingly important capability when
specific treatments targeting the JAK2 signaling pathway
become available.
JAK2
V617F is not observed in well-defined MDS cases
with marrow fibrosis in our cohort. This suggests that this
mutation must play a minimal role, if any, in the fibrosis
that occasionally occurs in MDS. However, it remains
controversial whether JAK2
V617F is associated with MDS
with fibrosis. Initially, a report by Ohyashiki et al.,
described the presence of JAK2
V617F in two of six MDS
cases with fibrosis, but it was absent in multiple cases of
AML, lymphoma, chronic myeloid leukemia with fibrosis,
and MDS without fibrosis [33]. However, the results of our
cohort and another study by Kremer et al. do not support
that hypothesis [34]. In agreement with our findings, they
also reported that JAK2
V617F is exceedingly rare in bona
fide MDS or de novo AML, regardless of the presence or
absence of fibrosis [34].
The optimal assays used to detect JAK2
V617F in the
setting of marrow fibrosis should be highly sensitive and
capable of using formalin-fixed materials as described here.
Of note, although the markedly hemodiluted marrow
smears and clot sections associated with bone marrow
fibrosis are suboptimal for morphological evaluation, they
contained a sufficient number of clonal hematopoietic cells
for successful DNA extraction and molecular testing. In our
laboratory, this real-time PCR melting curve assay was
previously shown to have an analytical sensitivity of 5% (i.e.,
capable of detecting 5 JAK2
V617F-positive cells per 100 total
cells) [20, 21]. This sensitivity may at least partially attribute
to the higher percentages of PMF patients carrying
JAK2
V617F in our cohort than reported in the literature [4–
19]. Other explanations would include biased sampling in
our cohort and different types of samples tested between
our study (predominantly archived marrow samples) and
other studies (predominantly using fresh blood samples).
Additionally, the possibility of a case selection bias for
JAK2
V617F screening in the cited studies cannot be
excluded. Furthermore, at times, when additional marrow
aspirate slides are not available, the ability to test for this
mutation using formalin-fixed clot sections will eliminate
the need for subsequent phlebotomies that can significant-
ly prolong turnaround time.
In summary, our results demonstrate that JAK
V617F is
very frequently identified in fibrotic bone marrow speci-
mens associated with BCR/ABL negative MPN, but it is not
observed in MDS with marrow fibrosis. These findings
indicate that the evaluation of JAK2 mutation status is an
important tool that may aid the diagnosis of patients with
marrow fibrosis.
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